The World Orphan Drug Congress is a renowned annual event that gathers experts, stakeholders, and advocates in the field of rare diseases. This year, the event promises to be more significant than ever, with high-profile patient-centric organisations like EURORDIS, Beacon for Rare Diseases , FEDER, CIBER-ER and many others. Amongst this years speakers is Eva Molero Romen, CEO of Barcelona-based research management organisation Teamit. She will take part in the pre-congress workshop “The evolving world of drug repurposing” scheduled for Monday, 30 October at the Intercontinental Hotel.
Eva Molero will speak on the topic of “REMEDi4ALL – A new European consortium to drive drug repurposing”. Drug repurposing, the practice of finding new uses for existing drugs, has gained significant attention for its potential to address rare diseases efficiently. Eva Molero’s is a knowledgeable voice in this field, especially because of her major role within the REMEDi4ALL project.
Adding to the discussions will be other experts such as Virginie Hivert, Anton Ussi, Marjon Pasmooij, and Anneliene Jonker. Indeed, the panel discussion on sustainability in repurposing and the impact of the changing regulatory landscape will be moderated by Beacon CEO Rick Thompson. In a time when more clarity is needed for regulatory challenges and opportunities in drug repurposing, this conversation is not to be missed!
Eva Molero’s presence in the workshop and her active involvement in this dialogue further exemplify the collaborative nature of the World Orphan Drug Congress. The event creates a unique space where different stakeholders come together to address the difficulties faced in the rare disease community and work towards innovative solutions. With reputable partnerships and interesting speakers, this year’s congress promises to be a milestone in the ongoing efforts to improve the lives of those affected by rare diseases.
